Literature DB >> 7637045

Papaverine-phentolamine and prostaglandin E1 versus papaverine-phentolamine alone for intracorporeal injection therapy: a clinical double-blind study.

O Shenfeld1, J Hanani, A Shalhav, Y Vardi, B Goldwasser.   

Abstract

PURPOSE: A study was designed to compare intracorporeal injections of papaverine plus phentolamine (2-drug solution) and papaverine plus phentolamine and prostaglandin E1 (3-drug solution) for the treatment for impotence.
MATERIALS AND METHODS: A total of 20 impotent patients received intracorporeal injections of the 2-drug or 3-drug solution alternately during 2 sessions, and the quality and duration of erections were assessed.
RESULTS: Of the patients 73% achieved a full erection with the 3-drug solution compared to 28% with the 2-drug solution. The average duration of erections was 57 minutes and 33.6 minutes, respectively. The complication rate was similar for the 2 treatments.
CONCLUSIONS: Papaverine plus phentolamine and prostaglandin E1 is superior to papaverine plus phentolamine alone for the treatment of impotence.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7637045

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  3 in total

1.  Extending the rationale of combination therapy to unresponsive erectile dysfunction.

Authors:  Christopher Reece; Rajeev Kumar; Diedre Nienow; Ajay Nehra
Journal:  Rev Urol       Date:  2007

2.  Papaverine plus prostaglandin E1 versus prostaglandin E1 alone for intracorporeal injection therapy.

Authors:  T F Zaher
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

Review 3.  Intracavernous alprostadil. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in erectile dysfunction.

Authors:  A P Lea; H M Bryson; J A Balfour
Journal:  Drugs Aging       Date:  1996-01       Impact factor: 3.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.